Larry L. Kestin, MD, FACR, FASTRO has authored over 100 peerreviewed journal publications and over 200 abstracts and several book chapters. He is a radiation oncology written and oral boards examiner for the American Board of Radiology and Chair of the Lung/Sarcoma section. He is a member of the NCI Thoracic Malignancy Steering Committee and has been a member of multiple ASTRO Committees. He has held academic appointments as a full professor at Oakland University and UCLA and was Program Director for the Department of Radiation Oncology at William Beaumont Hospital. He is actively involved in clinical research and has served as Principal Investigator for many local as well as national clinical trials.
- GenesisCare - Medical Director, Michigan Region, Farmington Hills, MI
- GenesisCare - National Director of Thoracic and Lung Services, Farmington Hills, MI
- Oakland University William Beaumont School of Medicine - Full Professor, Royal Oak, MI
- Oakland Community College - Full Professor, Bloomfield Hills, MI
- University of Missouri, BS, Computer Science, Columbia, MO
- University of Kansas School of Medicine, Kansas City, KS
- William Beaumont Hospital, Radiation Oncology, Chief Resident, Royal Oak, MI
- William Beaumont Hospital, Rotating Program, Royal Oak, MI
Expertise And Interests
- Lung / Thoracic, Lymphoma, Sarcoma, Prostate, GenitoUrinary Malignancies, Breast
Awards and honors
- Best Doctors in America &
- Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.
- Cardiac Dose in Locally Advanced Lung Cancer: Results from a Statewide Consortium.
- In Vivo Verification and Daily and Cumulative Dose Recalculation for Helical Tomotherapy: Multi Center Validation Based on Greater than 150,000 Daily Fractions Delivered
View 1 more
E. Arrojo, E. Fernandez, L. Kestin, A. Martinez, 2016, ACROView Presentation
Martinez A, Olivera G, Ghilezan M, Forman J, Kestin L, Finkelstein S, Mo X, Key S, Mantz C, Fernandez E, Galmarini D, et al., 2015, ASTRO Annual MeetingView Presentation
Kestin L, Fernandez E, Mantz C, Olivera G, Mo X, Key S, Finkelstein SE, Martinez A, Galmarini D., 2015, ASTRO Annual MeetingView Presentation
View 1 more
Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.View Study